Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care

ACTON, Mass.--(BUSINESS WIRE)--Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care.

Business Wire • Feb 5, 2026

Here's Why Insulet (PODD) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jan 26, 2026

Is Insulet (PODD) the Future of Diabetes Management?

Explore the exciting world of Insulet (PODD 1.20%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

The Motley Fool • Jan 21, 2026

Is PODD A Better Bet Than ISRG Stock?

PODD is Intuitive Surgical's counterpart in the Health Care Equipment sector that has:

Forbes • Jan 19, 2026

Insulet Corporation (PODD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Insulet Corporation (PODD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on.

Business Wire • Jan 9, 2026

Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its debut at Consumer Electronics Show (CES) 2026, where the Company will showcase its vision for liveable technology through an immersive booth experience, expert panel session, and media demonstrations. Liveable technology reflects Insulet's philosophy for the future of connected health: effortles.

Business Wire • Jan 6, 2026

Is it the Right Time to Add Insulet Stock to Your Portfolio?

PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.

Zacks Investment Research • Jan 2, 2026

Best Growth Stocks to Buy for December 31st

GLDD, CIEN and PODD made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 31, 2025.

Zacks Investment Research • Dec 31, 2025

3 Reasons Growth Investors Will Love Insulet (PODD)

Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research • Dec 26, 2025